DK3177646T3 - Cd3-bindingsdomæne - Google Patents
Cd3-bindingsdomæne Download PDFInfo
- Publication number
- DK3177646T3 DK3177646T3 DK15756850.2T DK15756850T DK3177646T3 DK 3177646 T3 DK3177646 T3 DK 3177646T3 DK 15756850 T DK15756850 T DK 15756850T DK 3177646 T3 DK3177646 T3 DK 3177646T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding domain
- domain
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gyroscopes (AREA)
- Optical Communication System (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3177646T3 true DK3177646T3 (da) | 2020-12-07 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15756850.2T DK3177646T3 (da) | 2014-08-07 | 2015-08-05 | Cd3-bindingsdomæne |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (show.php) |
| EP (2) | EP2982693A1 (show.php) |
| JP (1) | JP6669722B2 (show.php) |
| CN (1) | CN107001468B (show.php) |
| AU (1) | AU2015299039B2 (show.php) |
| BR (1) | BR112017002422B1 (show.php) |
| CA (1) | CA2957462C (show.php) |
| DK (1) | DK3177646T3 (show.php) |
| HR (1) | HRP20202024T1 (show.php) |
| HU (1) | HUE051919T2 (show.php) |
| LT (1) | LT3177646T (show.php) |
| RU (1) | RU2742691C2 (show.php) |
| SI (1) | SI3177646T1 (show.php) |
| WO (1) | WO2016020444A1 (show.php) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9493563B2 (en) | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| PL3387015T3 (pl) | 2015-12-09 | 2022-02-14 | F. Hoffmann-La Roche Ag | Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych |
| CA3013558C (en) | 2016-02-05 | 2024-11-12 | Universiteit Gent | CD8 LIAISON OFFICERS |
| TW201902512A (zh) | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3586872A4 (en) | 2017-02-24 | 2020-12-30 | Chugai Seiyaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION, ANTIGEN BINDING MOLECULES, METHOD OF TREATMENT AND METHOD OF SCREENING |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| EP3634998B8 (en) * | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| KR101973060B1 (ko) | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
| EP3765520A1 (en) | 2018-03-14 | 2021-01-20 | NovImmune SA | Anti-cd3 epsilon antibodies and methods of use thereof |
| SG11202009804RA (en) | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| TW202035451A (zh) * | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| CN112888482B (zh) | 2018-08-23 | 2024-06-25 | 里珍纳龙药品有限公司 | 抗Fcε-R1α(FCER1A)抗体，结合FCER1A和CD3的双特异性抗原结合分子及其用途 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| KR102899856B1 (ko) * | 2019-03-29 | 2025-12-15 | 주식회사 녹십자 | 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도 |
| BR112022014667A2 (pt) | 2020-01-29 | 2022-09-20 | Inhibrx Inc | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
| CN116261590B (zh) * | 2020-09-29 | 2025-10-17 | 信达生物制药(苏州)有限公司 | 抗cd3抗体以及其用途 |
| KR20240005691A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약 |
| KR20240005722A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약 |
| AR126161A1 (es) | 2021-06-17 | 2023-09-27 | Boehringer Lngelheim Int Gmbh | Moléculas de fijación triespecíficas novedosas |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| JP2025503573A (ja) | 2021-12-31 | 2025-02-04 | キィノ バイオテクノロジー カンパニー リミテッド | 抗ｇｐｒｃ５ｄ抗体及びその応用 |
| AU2023238766A1 (en) | 2022-03-23 | 2024-07-25 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| JP7701982B2 (ja) | 2022-04-13 | 2025-07-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| CN101575377B (zh) * | 1999-03-09 | 2012-12-26 | 津莫吉尼蒂克斯公司 | 作为zalpha受体之配体的人细胞因子及其用途 |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| SI1716178T1 (sl) | 2004-02-16 | 2010-11-30 | Micromet Ag | Manj imunogene vezne molekule |
| EP2612868B1 (en) * | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP2698431B1 (en) * | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
| NZ703939A (en) * | 2011-05-21 | 2016-01-29 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| WO2014106004A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| DK3030581T3 (da) * | 2013-08-07 | 2021-04-12 | Affimed Gmbh | Antistofbindingssteder, der er specifikke for egfrviii |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 HR HRP20202024TT patent/HRP20202024T1/hr unknown
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en not_active Ceased
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017105120A (ru) | 2018-09-10 |
| BR112017002422B1 (pt) | 2024-02-20 |
| CA2957462A1 (en) | 2016-02-11 |
| CN107001468B (zh) | 2021-04-09 |
| HUE051919T2 (hu) | 2021-04-28 |
| RU2742691C2 (ru) | 2021-02-09 |
| US20160039934A1 (en) | 2016-02-11 |
| SI3177646T1 (sl) | 2021-04-30 |
| EP3177646B1 (en) | 2020-10-07 |
| LT3177646T (lt) | 2021-01-11 |
| RU2017105120A3 (show.php) | 2019-02-20 |
| AU2015299039A1 (en) | 2017-03-02 |
| HRP20202024T1 (hr) | 2021-02-19 |
| EP2982693A1 (en) | 2016-02-10 |
| EP3177646A1 (en) | 2017-06-14 |
| WO2016020444A1 (en) | 2016-02-11 |
| JP2017529067A (ja) | 2017-10-05 |
| CA2957462C (en) | 2023-10-17 |
| JP6669722B2 (ja) | 2020-03-18 |
| US10066015B2 (en) | 2018-09-04 |
| CN107001468A (zh) | 2017-08-01 |
| BR112017002422A2 (pt) | 2017-11-28 |
| AU2015299039B2 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3177646T3 (da) | Cd3-bindingsdomæne | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| DK3411065T3 (da) | Clec9a-bindingsmidler | |
| DK3466976T3 (da) | Anti-her2-antistof-lægemiddelkonjugat | |
| DK3143042T3 (da) | Forbedrede variable immunoglobulindomæner | |
| DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
| IL247299B (en) | Complement component c5 antibodies | |
| EP3327220A4 (en) | BINDING MACHINE | |
| MA55696A (fr) | Combinaisons | |
| IL291164A (en) | Anti-nme antibody | |
| LT3166970T (lt) | Patobulinti a-beta protofibriles surišantys antikūnai | |
| DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
| EP3327221A4 (en) | BINDING MACHINE | |
| EP4230711C0 (en) | BRIQUETTES | |
| IL304203A (en) | Complement component c5 antibodies | |
| PL3122568T5 (pl) | Książeczka zabezpieczona | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| LT3178931T (lt) | Anti-orai1 antikūnas | |
| LT3126391T (lt) | Hpa-1a antikūnai | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| IL251479B (en) | Compositions | |
| DK3334807T3 (da) | Ildtænder | |
| DE112015004799A5 (de) | Schwungrad | |
| UA32044S (uk) | Чохол | |
| DE112015004618A5 (de) | Garnitur |